BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.

Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a ...

Brain metastases remain a defining challenge in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer ...

New EGFR-targeting combos may improve response rates and durability for patients with head and neck cancer.

It is well known that students who prepare in advance perform better in exams. Now, it appears that the skin can do the same.

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 9, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) ...

She emphasizes the importance of self-advocacy and giving oneself grace during survivorship. Support communities like ...

Introduction Skin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment ...

Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.

Glioma remains one of the deadliest brain cancers, characterized by aggressive growth and limited treatment options. In a new study, researchers from Ningxia Medical University uncovered that choline ...

Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...

The company has raised over $130 million since the start of 2025 through a combination of non-dilutive milestone payments, ...